Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Items 1,001–1,100 of 2,053
Trolle, C., Christensen, M., & Hansen, K. W. (2024) · Diabetic Medicine · doi:10.1111/dme.15298 · Cited by 4
“20,21 These guidelines have also been implemented in Denmark.”
BackgroundAberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Menzen, M., Selig, L., Mai, K., & Blüher, M. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6797 · Cited by 2
Giorgino, F., Guja, C., Aydın, H., Lauand, F., Melas‐Melt, L., & Rosenstock, J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111604 · Cited by 2
Rørth, R., Gerds, T. A., Kosjerina, V., Carstensen, B., Persson, F., & Rossing, P. R. (2025) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2025.100286 · Cited by 2
Self-citationPrandial Insulins: A Person-Centered Choice
Attri, B., Nagendra, L., Dutta, D., Shetty, S., Shaikh, S. S., Kalra, S., & Bhattacharya, S. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01540-8 · Cited by 3
“Various algorithms have been proposed for initiating and titrating basal-bolus regimens [3, 135, 168–170].”
Winkler, G., Folyovich, A., Kis, J. T., Dancs, T., & Schandl, L. (2024) · Orvosi Hetilap · doi:10.1556/650.2024.33012 · Cited by 2
Kuryłowicz, A., Babicki, M., Wąsowski, M., Jankowski, P., Kapusta, J., & Chudzik, M. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29586 · Cited by 3
Tomlinson, B., & Chan, P. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2341882 · Cited by 2
“…recommend SGLT2 inhibitors or GLP-1 RAs with proven cardiovascular disease benefits as potential first line treatment for patients with T2D and established atherosclerotic cardiovascular disease (ASCVD) or those with high risk of ASCVD or with chronic kidney disease or heart failure [5,6].”
BackgroundDang, A. K., Vu, B. N., Lam, T. P., Ho, T. K. T., Nguyen, A. K. T., Le, H. T., Mamun, A. A., Phung, D. T., & Thai, P. K. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111691 · Cited by 3
He, Z., Yamana, H., Yasunaga, H., Li, H., & Wang, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1385583 · Cited by 6
Kukova, L., Munir, K. M., Sayeed, A., & Davis, S. N. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2401589 · Cited by 3
“If those alone are not sufficient in achieving glycemic control, another antihyperglycemic agent should be added based on the individual’s comorbidities and the agent’s side-effect profile [4].”
InfluentialCHENG, A. Y. Y., Mauricio, D., Ritzel, R. A., Al‐Sofiani, M. E., Bailey, T. S., Mabunay, M. A., Bonnemaire, M., Melas‐Melt, L., Mimouni, S., & Davies, M. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111871 · Cited by 2
Self-citationBlanco-Vega, D. D., Reyes‐López, A., Vargas-Neri, J. L., & Osnaya-Valencia, F. I. (2024) · Pharmacy · doi:10.3390/pharmacy12050148 · Cited by 6
“Effective management involves both pharmacological and nonpharmacological treatments to regulate glucose levels and reduce the risk of microvascular and macrovascular complications [2].”
BackgroundSu, H., Nguyen, T. T. D., Lin, W., Ou, H., & Kuo, S. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02443-4 · Cited by 2
“For instance, the control of comorbid hypertension is considered important in current clinical management for patients with T2D [19], but most hypertensive cases in the UKPDS-OM2 model remained untreated given the few available treatment strategies and associated clinical recommendations at the…”
BackgroundThe risk of cancer among insulin glargine users in Lithuania: A retrospective population-based study
Jonušas, J., Drevinskaitė, M., Linkevičiūtė-Ulinskienė, D., Ladukas, A., Patašius, A., Zabulienė, L., & Smailytė, G. (2024) · Open Medicine · doi:10.1515/med-2024-1017 · Cited by 2
“Both organizations stress that the bene fi ts of good glycaemic control with insulin treatment, including insulin glargine, outweigh the potential risks [41,42].”
BackgroundNørlev, J. T. D., Kronborg, T., Jensen, M. H., Vestergaard, P., Hejlesen, O. K., & Hangaard, S. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241296828 · Cited by 4
Loh, W. J. (2024) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000892 · Cited by 4
“The class GLP-1 RA was initially developedbased on its hormonal mechanism of action that stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon secretion in hyperglycaemia or euglycaemia, decreasing appetite, and delaying gastric emptying [10].”
Wang, W., Han, Y., Jiang, X., Shao, J., Zhang, J., Zhou, K., Yang, W., Pan, Q., Nie, Z., & Guo, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16095 · Cited by 2
Entzündungskrankheiten: Was leistet eine antientzündliche Ernährung?
Geisler, C., Dörge, M., & Laudes, M. (2024) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2157-8898 · Cited by 2
Nanostructure-Based Drug Delivery in Alleviating Type 2 Diabetes Mellitus
Saini, A., Nagar, L., Panwar, R., Pahwa, R., Dua, K., Dureja, H., & Verma, P. K. (2025) · BioNanoScience · doi:10.1007/s12668-024-01786-2 · Cited by 2
McEwan, P. C., FOOS, V., Roberts, G. M., Jenkins, R. L., Evans, M., Wheeler, D. C., & Chen, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16141 · Cited by 3
“4,5,23 The CCA determines patient eligibility for either an SGLT2i or GLP-1 RA, which class is required, and whether it is administered.”
Heald, A. H., Stedman, M., Paisley, A. N., Jude, E. B., Habte‐Asres, H. H., Gibson, M., Forbes, A., & Whyte, M. (2025) · Diabetic Medicine · doi:10.1111/dme.15520 · Cited by 2
“11,12 A new glycaemic measure, personalised HbA1c (pHbA1c), 13 was developed from first principles to calculate a value equivalent to the laboratory-measured HbA1c from the average measured by CGM that may address the inaccuracies of HbA1c as a measure of glycaemia by accounting for interindividual…”
Sibon, I., Mohammedi, K., Quignot, N., Read, S. H., Kapnang, R., Khachatryan, A., Kikuchi, K., Ren, H., Massien, C., Vigié, L., et al. (2025) · European Stroke Journal · doi:10.1177/23969873251319172 · Cited by 2
Launbo, N., Pedersen, H., van Elst, C., Grunnet, L. G., Færch, K., Finlayson, G., Quist, J. S., & Beaulieu, K. (2025) · Appetite · doi:10.1016/j.appet.2025.107927 · Cited by 2
“The guidelines are developed from the Danish National Dietary guidelines (The Official Dietary Guidelines – good for health and climate, 2021) and the consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (Davies et al., 2022).”
Personalised type 2 diabetes therapy in primary care
Seidu, S. I., & Ikhile, D. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02844-7 · Cited by 2
Mahmood, N. M. S., Mahmud, A. M. R., & Maulood, I. M. (2025) · Nitric Oxide · doi:10.1016/j.niox.2025.02.003 · Cited by 3
Chaudhary, R. K., Ali, O., Kumar, A., Kumar, A., & Pervez, A. (2025) · Cureus · doi:10.7759/cureus.80495 · Cited by 11
“Patients with double diabetes and hypertension should follow the DASH (Dietary Approaches to Stop Hypertension) dietary plan because it leads to a better lipid profile, along with blood pressure enhancement [69].”
Romera, I., Redondo‐Antón, J., Santos, M. R., Díaz‐Cerezo, S., Artime, E., Rafels-Ybern, À., Ortega, E., & Conget, I. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01727-6 · Cited by 5
“%) or less [15].”
InfluentialWalewangko, O. C., Purnomo, J. S., Jo, P. A., Vidian, V., & Jo, J. (2025) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2025.14.e11 · Cited by 3
“…support) as well as using pharmacological treatments (insulin, metformin, glucagon-like peptide 1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, gastric inhibitory polypeptide, dipeptidyl peptidase 4 inhibitors, thiazolidine-diones and the 2nd generation of sulfonylurea) [7].”
InfluentialChoudhary, P., Paldánius, P. M., SALTER, J. E., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251331069 · Cited by 2
“11,27 These results suggest that this model is accurate at different glycemic levels and can differentiate between values close to this important threshold.”
Osman, A. A., Tayeb, B. A., Metzendorf, M., Bongaerts, B. W. C., Mohammed, N., Njangiru, I. K., & Franco, J. V. A. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015952 · Cited by 2
Chen, C., Hsu, S., & Chien, L. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112216 · Cited by 2
Carroll, O., Bidulka, P., Basu, A., Adler, A., O’Neill, S., Briggs, A. H., Lugo-Palacios, D. G., Khunti, K., & Grieve, R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16447 · Cited by 4
“3,4 We did not find any evidence of additional improvement in outcomes following second-line treatment with SGLT2i versus DPP4i or SU according to CVD status.”
Johansen, M. Y., Durrer, C. G., Pilmark, N. S., Legaard, G. E., Karstoft, K., Hansen, K. B., MacDonald, C., Almdal, T., Bjørner, J. B., Albrechtsen, N. J. W., et al. (2025) · Journal of sport and health science/Journal of Sport and Health Science · doi:10.1016/j.jshs.2025.101059 · Cited by 3
Alsan, M. M., Cawley, J., Doyle, J. J., & Skelley, N. (2025) · AEA Papers and Proceedings · doi:10.1257/pandp.20251065 · Cited by 2
A novel high dimensional approach to assess heterogeneous treatment effect in claims data
Wang, T., Pate, V., Wyss, R., Buse, J. B., Kosorok, M. R., & Stürmer, T. (2025) · American Journal of Epidemiology · doi:10.1093/aje/kwaf127 · Cited by 3
Self-citationCross-prevalence of large and small vessels disease in T2DM: overview from a Belgian academic centre
Lurquin, F. O., Petit, E. L., Ahn, S. A., Rousseau, M. F., & Hermans, M. P. (2025) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2025.2524239 · Cited by 2
Pantanetti, P., Ronconi, V., Mancin, S., Carolis, C. D., Alberti, S., Pazzi, O., Marco, S. D., Michetti, G., Coacci, S., Mignini, V. E., et al. (2025) · Diabetology · doi:10.3390/diabetology6080080 · Cited by 3
Integrated biomarker analysis and next-generation AI for precision diabetes prediction
Sim, H., Ha, H., & Kim, H. (2025) · Toxicological Research · doi:10.1007/s43188-025-00312-0 · Cited by 4
Impaired Efferocytosis of Pericytes and Vascular Smooth Muscle Cells in Diabetic Retinopathy
Gardiner, T. A., Little, K., & Stitt, A. W. (2025) · Cells · doi:10.3390/cells14171349 · Cited by 2
“This includes technical innovations in glucose monitoring and insulin delivery resulting in improved glycemic control for type-1 diabetes, and more so in view of the increased complexity of the therapeutic background in patients receiving treatment for type 2 diabetes [210].”
Ge, L.-C., Zhang, Y., Peng, G., Long, M., Jin, T., Lu, B., Shao, J., & Li, X. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i10.111548 · Cited by 3
Popovic, D. S., Stoian, A. P., & Παπάνας, Ν. (2023) · Endocrine · doi:10.1007/s12020-022-03294-3 · Cited by 2
“In type 2 diabetes mellitus (T2DM), glucagon-like peptide-1 receptor agonists (GLP-1 RAs) now have a prominent role in therapeutic algorithms by virtue of their beneficial cardiorenal effects, as documented in cardiovascular outcome trials (CVOTs) [2].”
BackgroundPermanent neonatal diabetes mellitus in a young Ukrainian child
Furdela, V., Pavlyshyn, H., Korytskyi, H., & Filiuk, A. V. (2016) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.18544/pedm-22.03.0061 · Cited by 2
van Walraven, C. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.200426 · Cited by 3
Popovic, D. S., Stoian, A. P., & Παπάνας, Ν. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108338 · Cited by 2
Fat – pharmacological therapies
Bain, S. C. (2022) · British Journal of Diabetes · doi:10.15277/bjd.2022.367 · Cited by 2
Use of GLP-1 analogs in the treatment of obesity: an integrative and systematic review
Furlan, G. B., Storto, M. E. B. M., da Silva, N. A. M., Corrêa, M. M. D. S. A., de Oliveira, B. R., Filho, D. R., & Neto, D. R. (2023) · International Journal of Nutrology · doi:10.54448/ijn23105 · Cited by 2
A „másik” inkretin – a glükózdependens insulinotrop polipeptid terápiás újrafelfedezése
Winkler, G., Kis, J. T., & Schandl, L. (2023) · Orvosi Hetilap · doi:10.1556/650.2023.32710 · Cited by 5
SGLT-2 Inhibitors: Discrepancy Between MACE Reduction and Incident MI and Stroke
Broome, D. T. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad216 · Cited by 2
Continuous glucose monitoring in diabetes
Moe, S. S., Kolber, M. R., & Falk, J. (2023) · Canadian Family Physician · doi:10.46747/cfp.6906406 · Cited by 3
Cha, E., Joung, K. H., Shin, Y., Son, N., Kim, H. J., & Faulkner, M. S. (2023) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106231192362 · Cited by 2
Chen, X., Hou, X., Gao, J., Yu, X., Zeng, W., Lv, R., Yang, X., & Liu, Y. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15380 · Cited by 2
A dipeptidil-peptidáz-4-gátlók szerepe a 2-es típusú diabetes mellitus kezelésében napjainkban
Harangi, M., Tóth, N., & Katona, Ë. (2023) · Diabetologia Hungarica · doi:10.24121/dh.2023.6 · Cited by 1
Twenty‐four‐hour physical behaviour profiles across type 2 diabetes mellitus subtypes
Henson, J. J., Tziannou, A., Rowlands, A. V., Edwardson, C. L., Hall, A. P., Davies, M. J., & Yates, T. E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15437 · Cited by 6
“11 In particular, these guidelines incorporate a growing body of evidence linking health outcomes associated with T2DM to physical behaviours over the whole, 24-h day.”
BackgroundSelf-citationGolembiewski, E. H., Bautista, A. E. G., Polley, E. C., Umpierrez, G. E., Galindo, R. J., Brito, J. P., Montori, V. M., Gockerman, J. P., Tesulov, M., Labatte, B., et al. (2024) · Clinical Diabetes · doi:10.2337/cd23-0042 · Cited by 2
Kesavadev, J., Ashik, A., Yasmin, S., Raj, K. S., Krishnan, G., Basanth, A., & Shankar, A. (2023) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_33_23 · Cited by 3
Conde, S. V., Sacramento, J. F., Zinno, C., Mazzoni, A., Micera, S., & Guarino, M. P. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1378473 · Cited by 3
Lee, S., Liu, T., Chung, C. T., Reinhold, J., Vassiliou, V. S., & Tse, G. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00012-7 · Cited by 5
Care of Diabetes and the Sacrifice of Evidence-Based Medicine and Health Equity
Goldberg, D. N. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08907-3 · Cited by 2
Wilk, M., Horodnicka‐Józwa, A., Molęda, P., Petriczko, E., Safranow, K., & Walczak, M. (2016) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.18544/pedm-22.04.0062 · Cited by 2
Warnaya, C. I., Larasanty, L. P. F., Meryta, L. P. A., Divacandraningrat, I. D. A. A., Iswari, W. R., Deviyanthi, I. A. S., & Sarasmita, M. A. (2020) · Jurnal Farmasi Udayana · doi:10.24843/jfu.2020.v09.i01.p03 · Cited by 3
Innovative Ways of Treating Diabetic Peripheral Neuropathy in the United States: A Narrative Review
Joseph, S. (2022) · Open Access Journal of Endocrinology · doi:10.23880/oaje-16000173 · Cited by 1
Hwang, I., Kim, Y., Yoo, H., Jang, I., Yu, K. S., & Lee, S. (2020) · doi:10.22541/au.159225448.88533971 · Cited by 1
Lubaki, J.-P. F., Omole, O. B., & Francis, J. M. (2022) · Research Square · doi:10.21203/rs.3.rs-1788561/v1 · Cited by 2
Commentary on cardiovascular safety of DPP4Is: Focus on Alogliptin
Trailokya, A., Zargar, A. H., TIWASKAR, M. H., Kale, S. R., & Shirsat, A. (2023) · Indian Journal of Pharmacy and Pharmacology · doi:10.18231/j.ijpp.2023.013 · Cited by 3
Hanlon, P., Butterly, E. W., Wei, L., Wightman, H., Almazam, S. A., Alsallumi, K., Crowther, J., McChrystal, R., Rennison, H., Hughes, K., et al. (2024) · medRxiv · doi:10.1101/2024.06.23.24309242 · Cited by 2
Koçyiğit, E., Karadağ, M. G., Aktürk, M., & Varis, A. (2025) · Research Square · doi:10.21203/rs.3.rs-5920397/v1 · Cited by 2
Obi, M. F., Ahmad, S., & Ezechukwu, K. (2026) · Cureus · doi:10.7759/cureus.106266 · Cited by 1
“Ironically, patients with multiple comorbidities, who stand to benefit most from the cardiorenal protective effects of these medications, often encounter the greatest difficulty obtaining timely access [10].”
InfluentialMahboub, B. M., El-Haggar, S. M., Abdelraouf, Y. M., & El-Azab, G. A. (2019) · doi:10.35248/2155-6156.19.10.834 · Cited by 1
Lisco, G., & Triggiani, D. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230227113252 · Cited by 1
Ken-Opurum, J., Srinivas, S. S. S., Jain, D., Shah, T., Samnaliev, M., DEX, T. A., Charland, S. L., Revel, A., & Preblick, R. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01477-3 · Cited by 1
“…peptide 1 receptor agonists (GLP-1RA), and sodium–glucose cotransporter 2 inhibitors (SGLT2i) depending upon the goal of their therapy [5, 6]; however, evidence suggests the need for treatment intensification for patients with T2DM who fail to achieve target glycated hemoglobin (HbA1c)…”
BackgroundThe Characteristics and Risk of Mortality in the Elderly Korean Population
Suh, S. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.502 · Cited by 1
Alluhidan, M., Alabdulkarim, H. A., Alrumaih, A. M., Alturaiki, A., Alshahrani, A. M., AL-Qahtani, S. S., Alhossan, A., & Al-Jedai, A. H. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2277056 · Cited by 2
“6,9,10 Oral semaglutide, recently allowed as first-line therapy through a US Food and Drug Administration label update for adults with T2DM, is an intervention that is easier to prescribe and adhere to and may help address some of the physician and patient barriers that prevent improved glycemic…”
BackgroundEfecto del Disolvente en la Conformación Estructural de la Glibenclamida
Almazan, M. I. C., Mena, R. R. F., Martínez, L. A. M., et al. (2023) · Quimica Hoy · doi:10.29105/qh12.03-335 · Cited by 1
RELACIÓN ENTRE AUTOCUIDADO Y ESTIGMA ASOCIADO A LA DIABETES TIPO 2 EN ADULTOS MEXICANOS
Jiménez-González, Y., Santamaría, Y. R., Juárez-Medina, L. L., Mendoza-Catalán, G. S., Luna, N. S. A., & Llano, A. L. J.-D. (2023) · Horizonte de enfermeria · doi:10.7764/horiz_enferm.num.esp.128-141 · Cited by 1
Commercially Available Injectables in Diabetes – Insulin, Incretins, and More
Kesavadev, J., Kalra, S., John, M., Unnikrishnan, A., Joshi, S., Sankar, P., Kumar, A., Jothydev, K., & Basanth, A. (2023) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_29_23 · Cited by 3
Evolution of Management of Diabetes Mellitus
Uddin, K. N. (2024) · Bangladesh Journal of Medicine · doi:10.3329/bjm.v35i1.70738 · Cited by 1
“This is in contrast to a one-size-fits-all approach, in which disease treatment and prevention strategies are developed with less consideration for the differences between individuals.. Compared with oncology, the role of precision medicine in diabetes management is less clear given the heterogeneous nature of T2DM, a…”
BackgroundInfluentialKrentz, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00001-2 · Cited by 1
Cardiometabolic Health: Actionable Prevention Strategies and New Care Models
Leonards, O., & Aguilar, D. A. (2024) · Texas Heart Institute Journal · doi:10.14503/thij-23-8275 · Cited by 1
Fixed ratio combinations GLP-1RA and basal insulin: literature review
Куркин, Д. В., Bakulin, D. A., Morkovin, E. I., Strygin, A. V., Gorbunova, Y. V., Волотова, Е. В., Robertus, A. I., Макаренко, И. Е., Saparova, V. B., Васильевич, Д. Р., et al. (2024) · Problems of Endocrinology · doi:10.14341/probl13312 · Cited by 5
Lu, Q., Lin, Y., & Li, Z. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s464017 · Cited by 1
Seok, J., & Lee, Y. (2024) · Nutrition Research and Practice · doi:10.4162/nrp.2024.18.2.239 · Cited by 1
“The consensus report by the American Diabetes Association and the European Association for the Study of Diabetes reveals that physical activity can have a significant impact on the cardiometabolism of T2DM [29].”
BackgroundNaidoo, B., Pillay, S., & Wilson, D. (2024) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2024.2325810 · Cited by 3
“4,5 12 However, the exact incidence of vitamin B12 deficiency among people living with diabetes remains uncertain, as does its contribution to the development of PN. Research from high-income countries indicates that vitamin B12 levels might inherently vary among different ethnic groups, with…”
Albajy, M. A., & Mihailescu, D. F. (2024) · Health Problems of Civilization · doi:10.5114/hpc.2024.136467 · Cited by 2
Fukuda, M., Sakuma, I., Wakasa, Y., Funayama, H., Kondo, A., Itabashi, N., Maruyama, Y., Kamiyama, T., Utsunomiya, Y., Yamauchi, A., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01575-w · Cited by 1
“The QOL of patients is also the focus of the consensus statement of the American Diabetes Association and European Association for the Study of Diabetes in addition to presence of pathological conditions and efficacy, side effects, and costs of medical agents [2].”
BackgroundVázquez, L. A., Tofé, S., Bellido, D., Botella-Serrano, M., Soto-González, A., Mezquita‐Raya, P., Delgado, E., Fajardo, C., Morales, C., Causanilles, A., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01587-6 · Cited by 2
Piya, M. K., & HOCKING, S. L. (2024) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2024.100784 · Cited by 1
Pedersen, Z. O., Jacobsen, S. S., Ewers, B., & Grabowski, D. (2024) · Nutrients · doi:10.3390/nu16111618 · Cited by 4
Bao, Y., Han, L., Du, L., & Ji, L. (2024) · Obesity · doi:10.1002/oby.24030 · Cited by 1
“Currently, an HbA1c target of 7.0% ( 53 mmol/mol) is recommended for most nonpregnant adults with type 2 diabetes [5, 7].”
BackgroundInfluentialLegacy effect of intensive glycaemic control in type 2 diabetes—the UKPDS
Rodríguez‐Gutiérrez, R. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01395-3 · Cited by 3
Li, S., Guan, C., Wang, Y., Chen, H., Li, W., Wang, S., Zhang, C., & Xing, X. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250206 · Cited by 2
“Inhibition of DPP-IV increases the availability of intact GLP-1 [9–11], making DPP-IV inhibitors a promising class of oral hypoglycemic agents for T2D patients [12].”
Glycemic variability and diabetic cardiac autonomic neuropathy
Serhiyenko, A. A., Tsaryk, T. V., Pavlovskiy, Y., & Serhiyenko, V. A. (2024) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.20.4.2024.1398 · Cited by 1
Lu, C., Su, S., & Kuo, F.-C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164590 · Cited by 3
“…with T2DM but also need to notice their body weight status with maintenance of physical activity for preserving lean mass and muscle strength, as recommended in the consensus report of the American Diabetes Associations (ADA) and the European Association for the Study of Diabetes (EASD) [7].”
BackgroundStrandberg, J., Gade, I. L., & Hviid, C. V. B. (2024) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2024.2378932 · Cited by 1
El-Bawab, E.-S. M. E.-S., Alomairi, M., Kabeer, A. M. E., & Abd-Allah, S. (2023) · Al-Azhar Assiut Medical Journal · doi:10.4103/azmj.azmj_22_24 · Cited by 1
Alghadeer, S. M., Mubarak, A. M., Alsuwayni, B. M., Al-Murdhi, F. M., Al-Malki, H. S., & Alotaibi, M. S. (2024) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2024.102168 · Cited by 1
“(Davies et al., 2022; American Diabetes Association, 2018) However, the use of insulin for patients with uncontrolled diabetes has been associated with negative cardiovascular outcomes compared to other anti-diabetic medications.”
BackgroundThe role of finerenone in the management of CKD in T2D –Practical considerations for primary care
Kanumilli, N., Miszon, M., Schnell, O., & Groop, P. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.09.001 · Cited by 3
Stoltenberg, C. W., Hangaard, S., Hejlesen, O. K., Kronborg, T., Vestergaard, P., & Jensen, M. H. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241280096 · Cited by 1
“3,8 Insulin therapy is often initiated with long-acting options in people with type 2 diabetes; however, many will eventually require additional fast-acting insulin before or at the time of meals to reach glycemic target.”
Cebada, A. B., Silva, J. B. Q., Escobar-Morreale, H. F., & Chávez, L. N. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.10.010 · Cited by 5
Abe, T., Takeda, Y., Sakuma, I., Okada, M., Kurigaki, A., Bessho, R., Sato, M., Kitsunai, H., Takiyama, Y., & Sakurai, M. (2024) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2024.0127 · Cited by 1
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.